Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Fun while it lasted
View:
Post by BottomBroker on Apr 28, 2023 11:53am

Fun while it lasted

Back down we go. *sigh*
Comment by M101 on Apr 28, 2023 12:16pm
I can hardly wait for the first poster to tell us how he got in at 6 and left at 11, and btw glta. 
Comment by M101 on Apr 28, 2023 12:56pm
This is where it gets interesting. If a minute oscillator said it had stalled at 11 then how many minutes does it take to reverse again at 9.50? 9000 shares traded at near 11 this morning so a few traders had an easy exit, but more interesting is the motivation of the buyers. No news, no gap, no bargain price at the open and yet almost $100,000 was bet that we are closer to the beginning than the ...more  
Comment by BottomBroker on Apr 28, 2023 1:06pm
I miss 4-cent David. *sigh again*
Comment by Ardbeg on Apr 28, 2023 3:58pm
Still wonder what drove it up? Unfortunately I agree, I'm guessing down back to where it started..
Comment by M101 on Apr 28, 2023 5:49pm
Lots of volume, momentum traders should all be out. And we're an AD vaccine company now, who doesn't want a piece of that? 
Comment by Ardbeg on Apr 28, 2023 9:50pm
I can't answer that, but I'm guessing lots of folks/companies might skip out on it. I do so very much hope I'm wrong about my guess and you are right!
Comment by M101 on Apr 28, 2023 10:40pm
Lol, well vaccines have never been less popular but I'm curious about your guess, why?   
Comment by M101 on May 01, 2023 11:48am
And....nothing, right back where the powers that be set the price upon arriving at Nasdaq. It's almost like momentum traders and weak hands just don't matter.
Comment by BottomBroker on May 01, 2023 12:19pm
One step forward, one step back. Same as it ever was. 
Comment by Speyeder999 on May 01, 2023 12:03pm
As far as vaccines go for AD, I think it's noteworthy to mention that our SAB chairman Rudy Tanzi was never a fan of a vaccine solution to begin with,  but I'm assuming Cashman's science must have swayed his beliefs and this should be  seen as a huge endorsement coming from a person with his credentials....I mean why else remain SAB if he wasn't on board?......just saying ...more  
Comment by M101 on May 01, 2023 1:29pm
Great point. Tanzi's beliefs are understandable in the context of his 2018 paper(s) re Herpes and the defensive role(s) of amyloid,  but it's just one more reason that extreme targeting is needed.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities